SCHEMBL4236294

SCHEMBL4236294

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4ccc(N)c(F)c4)cc3F)cc2C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 5/20 0.45
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
ADRA2C P18825 1/20 0.40
CHRM3 P20309 1/20 0.40
HTR1D P28221 1/20 0.40
ADRA1B P35368 1/20 0.40
HTR2B P41595 1/20 0.40
HTR3A P46098 1/20 0.40
PDE4D Q08499 1/20 0.40
HRH3 Q9Y5N1 2/20 0.39
HTR1F P30939 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
GPR6 P46095 1/20 0.37
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
POLB P06746 2/20 0.37
ERBB2 P04626 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237656 0.89 HTR4 (0.44) HTR4CHRM4CHRM5ADRA2CCHRM3
SCHEMBL4684563 0.89 KDR (0.44) PDE4DHRH3FLT1KDR
SCHEMBL4238603 0.88 HTR4 (0.42) HTR4CHRM4CHRM5ADRA2CCHRM3
SCHEMBL4236414 0.88 MAPT (0.46) PDE4DHRH3POLBMEN1MAPT
SCHEMBL4238014 0.88 PKM (0.40) HTR4PDE4DHRH3HTR1FGPR6
SCHEMBL4688854 0.86 CCR3 (0.45) FLT1KDRPOLBMEN1MAPT
SCHEMBL4229188 0.85 MCHR1 (0.40) PDE4DHRH3FLT1KDRPOLB
SCHEMBL4237553 0.85 WDR5 (0.45) HTR4PDE4DPOLBMEN1MAPT
SCHEMBL4688007 0.85 CCR3 (0.44) FLT1KDRPOLBMEN1MAPT
SCHEMBL4233470 0.84 MCHR1 (0.40) HRH3FLT1KDRPOLBERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R HTR4 102/4885CHRM4 149/4885CHRM5 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.